Oxygen in tumours predicts prostate cancer recurrence
Published: April 4, 2012
Low oxygen levels in tumours can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy - a breakthrough that could change the way their cancer is treated.
“We’ve not only shown that men do worse if they have low oxygen levels (hypoxia) in their prostate cancer, but that they also do worse over a shorter period of time,” said Dr. Michael Milosevic, a U of T professor of radiation oncology and radiation oncologist in the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN). “These patients seem to develop cancer recurrence within only a few years of completing treatment.”
The clinical research, led by radiation oncologists from the Ƶ and the PMH Cancer Program, (UHN) was published online in Clinical Cancer Research, a journal of the American Association for Cancer Research.
“This information could change the way prostate cancer is treated and goes a long way to ensuring that all patients receive the right treatment from the outset – based on their individual tumour,” Milosevic said. “At the heart of it, this is what personalized medicine is all about.”
Prostate cancer is commonly treated with surgery or radiation therapy, and yet cancer recurs or spreads in about 25 per cent of treated men. The discovery of indicators, such as low oxygen in tumours, enables doctors to better select the most appropriate and effective treatments for each patient even before radiation therapy is delivered.
Milosevic and colleagues measured oxygen levels in 247 men with localized prostate cancer prior to radiation therapy and followed them for a median of 6.6 years. Low oxygen in the tumours predicted early relapse after radiation treatment. It was also the only identified factor that predicted local recurrence during follow-up.
“We believe that a tumour’s genetic signature will be another promising predictor of recurrence,” said Dr. Robert Bristow, a professor in the departments of radiation oncology and medical biophysics at U of T and a radiation oncologist in the PMH Cancer Program, UHN. “Combined, these indicators may signal that the cancer has spread at a previously-undetectable level.”
Milosevic and colleagues hope that identifying the factors that influence prostate cancer behaviour will lead to the exploration of new drugs to target hypoxia in tumours. The findings may also accelerate the development of new treatment strategies – informing physicians when complementary treatment may be more effective.
“Knowing what works for which patient will make treatment more effective and improve outcomes for patients,” said Milosevic.
The research was funded by United States Army Prostate Cancer Research Program, Terry Fox Program Project Grant through the National Cancer Institute of Canada and Terry Fox Foundation New Frontiers Program Project Grant through the Canadian Cancer Society Research Institute. Milosevic’s research is also supported by The Princess Margaret Hospital Foundation.
